



ASX Announcement

31 October 2025

2025 Annual General Meeting – Chairman’s Address to Shareholder

In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (**Atomo**) attaches the Chairman’s Address to be delivered at Atomo’s 2025 Annual General Meeting.

For more information, please contact:

John Kelly

Managing Director & CEO

e. john.kelly@atomodiagnostics.com

p. +61 401 922 279

This announcement was authorised by the Managing Director & CEO on behalf of the Board



Good morning, everyone, and welcome to Atomo Diagnostics' Annual General Meeting. On behalf of the Board, I thank you for joining us today and for your continued support of the Company.

The past year has been one of both challenge and progress for Atomo. Despite a volatile operating environment across the global diagnostics sector, we have continued to execute our strategy of delivering innovative, user-centred rapid testing solutions that improve access to accurate and reliable diagnostics worldwide.

The shift to decentralised, at-point-of-care and self-testing solutions remains a strong structural trend. Government policy and regulators are continuing to see the benefits of point-of-care and self-testing. Think diabetes, a patient has been able to monitor themselves for years, and more recently the use of COVID Rapid Antigen Tests (RATs) in our homes – these are what we call point-of-care or self-testing.

Atomo's core purpose remains clear — to simplify and democratise diagnostic testing through our patented device technology. Our products are designed to make testing easier, safer, and more reliable, whether used by healthcare professionals or self-test users in the home.

Atomo's technology is proven, being the first HIV/AIDS self-test to be approved by the Australian Therapeutic Goods Administration (TGA).

Over the past year, we have:

- Advanced key commercial partnerships in both professional and self-testing markets;
- Continued to grow international regulatory approvals for Atomo's test devices;
- Streamlined our operating model to enhance efficiency and preserve capital; and
- Focused our R&D and business development activities on the highest-value opportunities in infectious disease and other rapid test applications.



Another example of Atomo's technology; Atomo is the exclusive licensor, manufacturer and supplier of the Pascal cassette to Lumos (ASX:LDX) for its FebriDx® product. Using Atomo's Pascal cassette, FebriDx® has previously secured 510k clearance from the US FDA and recently completed a CLIA waiver trial and submission to US FDA. The CLIA waiver trial showed that Pascal has enabled greater than 99% concordance between trained and untrained operators using FebriDx®.

CLIA waiver - What does this mean? CLIA waiver in the USA market is extremely important because it allows for simple, low risk diagnostic tests to be performed outside of the traditional laboratories, expanding access to timely and reliable healthcare. This opens up the various doctor office clinics and pharmacies

The Board recognises that the financial year has been challenging in terms of revenue growth and capital market conditions. Nevertheless, over the last few months our share price has increased, and company fundamentals have improved. We remain confident that the Company's technology platform, intellectual property, and strong global relationships position Atomo well to participate in the continuing evolution of decentralised diagnostics.

During the year we undertook a successful capital raising, supporting working capital and enabling us to reshape our organisation and position ourselves for the next growth phase. We want to thank existing and new shareholders for their support.

As I am sure you are aware the Company has refreshed the Board, with a focus on bringing in diagnostics/medical-device expertise and strengthening oversight and operational discipline.

In parallel, management has taken decisive steps to reduce costs and strengthen our balance sheet. This financial discipline will support our ability to pursue commercial opportunities in a sustainable manner while continuing to invest selectively in innovation.

Looking forward, Atomo 2.0 has emerged with a strategy centred on three priorities:

1. Expanding the commercial deployment of our existing device technology through partnerships and licensing;



2. Leveraging our proven platform in new testing applications where usability and accuracy are critical; and
3. Maintaining operational excellence and prudent capital management as we build towards profitability.

I would like to take this opportunity to thank my fellow Non-Executive Directors, Dr Cheri Walker & Mr Tony May, for their support and guidance. Also, our CEO/MD, John Kelly, who also took on the role of Interim Chair whilst the new Board got up to speed and the entire Atomo team for their dedication and professionalism throughout the year. Their efforts have ensured that Atomo continues to be recognised as a leader in user-centric diagnostic design and manufacturing.

I would also like to acknowledge the ongoing support of our shareholders. Your confidence in our vision enables us to continue driving innovation in an industry that plays such a vital role in global public health.

The Board remains committed to delivering long-term value through disciplined execution, strategic partnerships, and continued focus on innovation and quality.

Thank you once again for your attendance and support. I will now hand over to our CEO/MD, John Kelly, to provide further detail on the Company's operational and commercial progress during the year.

References:

- (1) LDX ASX Release: Lumos announces FebriDx CLIA Waiver Application Submission, 18-08-2025
and AT1 AXS Release: Update on Indicated Pascal Supply for FebriDx® 21-08-2025